# Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

> **NCT00104871** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Insular Thyroid Cancer
- Recurrent Thyroid Cancer
- Stage II Follicular Thyroid Cancer
- Stage II Papillary Thyroid Cancer
- Stage IV Follicular Thyroid Cancer
- Stage IV Papillary Thyroid Cancer

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00104871
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2010-05
- **Final completion:** 2014-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00104871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00104871, "Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00104871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*